期刊文献+

白介素-1家族在动脉粥样硬化中的作用 被引量:5

The Role of Interleukin-1 in Atherosclerosis
下载PDF
导出
摘要 动脉粥样硬化(AS)是一种慢性炎症性疾病。促炎细胞、促炎因子以及抗炎细胞、抗炎因子在此过程中发挥了重要作用,双方相互抑制,特定环境可相互促进,构成了一个复杂的炎症网络系统。平衡打破则表现为促炎活性升高和抑炎活性降低,可促进斑块的进展和不稳定,导致心血管事件。近年来白细胞介素(IL)-1家族在AS过程中的作用受到重视。依据其在AS进程中的作用,将其分为促AS家族,抗AS家族以及未归类成员。 Atheroselerosis (AS) is a chronic inflammatory disease, Proinflammatory cytokines and anti-inflammatory cytokines play an Important role in this process. They inhibition as well as promote each other, which constitute a large and complex inflammatory system. When this balance is broken, and that means proinflammatory factors play the dominant role in inflammatory process, acute cardiovascular events will happen. In recent years, the relationship between interleukin (IL)-I family attracted the attention of scientists. In this review, we divided the IL-1 family into promoting atherosclerosis members, anti-atherosclerosis members and uncategorized members.
作者 奚卉 洪涛
出处 《医学与哲学(B)》 2016年第3期55-57,共3页 Medicine & Philosophy(B)
关键词 动脉粥样硬化 白介素-1 促炎因子 抗炎因子 atherosclerosis, interleukin-1 (IL-1), inflammatory factor, antiinflammatory factor
  • 相关文献

参考文献32

  • 1Tabas I,Glass C K. Anti-inflammatory therapy in chronic disease~ chal- lenges and opportunities[J]. Science, 2013,339 (6116) : 166- 172. 被引量:1
  • 2Libby P. Inflammation in atherosclerosis[J]. Arterioscler Thromb Vase Biol,2012,32(9) :2045-2051. 被引量:1
  • 3Garlanda C, Dinarello C A, Mantovani A. The interleukin-1 family: back to the future[J]. Immunity,2013,39(6):1003-1018. 被引量:1
  • 4Kakkar R, Lee R T. The IL-33/ST2 pathway:therapeutic target and no- vel biomarker[J]. Nat Rev Drug Discov,2008,7(lO):827-840. 被引量:1
  • 5Dewberry R, Holden H, Crossman D, et al. Interleukin-1 receptor antagonist expression in human endothelial cells and atherosclerosis [J]. Arterioscler Thromb Vase Biol, 2000,20 (11) : 2394- 2400. 被引量:1
  • 6McCarty S, Frishman W. Interleukin lbeta: a proinflammatory tar- get for preventing atherosclerotic heart disease[J]. Cardiol Rev, 2014,22(4) :176-181. 被引量:1
  • 7Clarke M C, Talib S, Figg N L, et al. Vascular smooth muscle cell apoptosis induces interleukin-l-directed inflammation: effects of hy- perlipidemia mediated inhibition 2010,106(2) :363-372. 被引量:1
  • 8Kirii H,Niwa T,Yamada Y,et al of phagocytosis [J]. Circ Res Lack of interleukin-lbeta decrea ses the severity of atherosclerosis in ApoE-deficient mice[J]. Arte- rioscler Thromb Vase Biol, 2003,23 (4) : 656 - 660. 被引量:1
  • 9Merhi-Soussi F,Kwak B R, Magne D, et al. Interleukin-1 plays a major role in vascular inflammation and atherosclerosis in male apolipoprotein E-knockout mice[J]. Cardiovasc Res, 2005,66 (3) : 583- 593. 被引量:1
  • 10Hand T W. Interleukin-18: The Bouncer at the Mucosal Bar[J]. Ce11,2015,163(6) :1310-1312. 被引量:1

二级参考文献48

  • 1中国成人血脂异常防治指南[J].中华心血管病杂志,2007,35(5):390-419. 被引量:5233
  • 2Kannel W B,Dawber T R,Kagan A,et al. Factors of risk in the develop- ment of coronary heart disease six year follow-up experience. The Framingham Study[J]. Ann Intern Med, 1961,55 : 33-- 50. 被引量:1
  • 3Castelli W P. Epidemiology of coronary heart disease:the Framing- ham study[J]. Am J Med,1984,76(2A) :4--12. 被引量:1
  • 4LaRosa J C, Hunninghake D, Bush D, et al. The cholesterol facts. A summary of the evidence relating dietary fats, serum cholesterol, and coronary heart disease. A joint statement by the American Heart Association and the National Heart,Lung,and Blood Institu- te. The Task Force on Cholesterol Issues, American Heart Associa- tion[J]. Circulation, 1990,81 (5) : 1721 -- 1733. 被引量:1
  • 5Endo A,Kuroda M,Tsujita Y. ML-236A,ML-236B,and ML-236C, new inhibitors of cholesterogenesis produced by Penicillium citrini um[-J]. J Antibiot (Tokyo) ,1976,29(12) : 1346--1348. 被引量:1
  • 6Brown S, Goldstein J L. The Nobel Prizein physiology or medicine 1985[EB/OL]. [2015- 03- 02]. http://www, nobelprize, org/no- hel_prizes/medicine/laureates/1985 / press, html. 被引量:1
  • 7Scandinavian simvastatin survival study group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S)[J]. Lancet, 1994,344(8934) .. 1383-- 1389. 被引量:1
  • 8Streja L, Packard C J, Shepherd J, et al. Factors affecting low-densi ty lipoprotein and high-density lipoprotein cholesterol response to pravastatin in the West of Scotland Coronary Prevention Study (WOSCOPS)[J]. Am J Cardiol,2002,90(7) :731--736. 被引量:1
  • 9Sacks F M,Pfeffer M A,Moye L A,et al. The effect of pravastatin on coronary events after myocardial infarction in patients with aver- age cholesterol levels. Cholesterol and Recurrent Events Trial in- vestigators[J]. N Engl J Med, 1996,335(14) : 1001-- 1009. 被引量:1
  • 10Tonkin A,Aylward P,Colquhoun D, et al. Prevention of cardiovas- cular events and death with provastatin in patients with coronary heart disease and a broad range of initial cholesterol levels[J]. N Engl J Med,1998,339(19) :1349--1357. 被引量:1

共引文献21

同被引文献43

引证文献5

二级引证文献29

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部